Project HERO (Healthcare online)
As a group of scientists, immunologists, medical doctors and biochemists we feel that at the present time the most important tool we have to prevent SARS-CoV-2 infection is to physically distance the most vulnerable populations, either of advanced age or hematological patients, as well as physicians from the potential contact with the virus.
The Project goal
We propose here that the same specialist who diagnosed and treated the patient by inevitable face-to-face interaction can continue to take care of the patient remotely avoiding redundant hospital visits during the patient’s convalescence at home.
(CEI COVID-19 Extraordinary Call 2020)
Healthcare online HERO
will give support to our patients and improve the quality of the medical care which has been compromised with the Corona pandemic
With the HERO Project (Healthcare Online) we wish to assist patients recovering from hematologic malignancies. Our primary aim is to develop a telemedicine platform for patients that will enable them, as the most vulnerable group in the society during the current Corona crisis, to avoid physical contacts with other people and still to get a quality medical support from the comfort of their home.
Our target group will get an appointment with their own personal doctor for regular check-ups virtually, without taking risks of being exposed to SARS-CoV-2 or other viral infections by avoiding public transportation and hospital waiting rooms.
Yet, anamnesis, diagnosis and therapy for haematological diseases require a personal contact with medical professionals. Therefore, our project allows the convalescing patient to stay in contact with his personal doctor after returning home. Through an internet or telephone appointment the patient will be monitored and eventually will get a prescribed therapy adjustment though safe from physical contact.
The educational aim of the project will facilitate the patients’ access to information needed during treatment and recovery.
Our additional goal is to improve the knowledge of the general population and especially the target group of patients with leukemia as a population that is at major risk of COVID-19 infection.
- Prof. Mariastefania Antica, PhD, SCYM (ASCP) Senior scientist with tenure
- Dr. Lipa Čičin-Šain, PhD
Senior scientist with tenure
- Darko Heckel, DVM
Ruđer Bošković Institute
- Prof. Isabella Screpanti, MD,PhD
Professor of immunology
- Prof. Guilio Caracciolo, MD,PhD
Professor of molecular medicine
Sapienza University of Rome
- Dr. Sanja Novak,PhD
University of Connecticut, Connecticut, USA
- Marsela Mišković, design student
Faculty of Graphic Art
- Assist. Prof. Delfa Radić-Krišto, MD, PhD
Head of the Clinic for Internal Medicine
- Assist. Prof. Anita Škrtić,
MD, PhD, Director of Surgical Pathology, Department
of Pathology and
- Assist. Prof. Gordana Kaić, MD, PhD, Head of the Department of Clinical Cytology and Cytogenetics
University Hospital Merkur
- Prof. Valentin Shichkin, MD,PhD
Professor of immunology
Open International University of Human Development “Ukraine” Kiev, Ukraine
- Assist. Prof. Aleksandra Maršavelski, PhD
Specialist in computational biochemistry